title: [The Arg16Glybeta2-adrenergic receptor polymorphism influences long term clinical responses to beta2-agonist].
abstract: BACKGROUND
  The coding region variant Arg16Gly at the beta2-adrenoceptor gene (ADRB2) is functionally relevant, and is common in Japanese. Longer term clinical responses to short-acting and long-acting beta2 agonists have been influenced by the Arg16Gly polymorphism. The purpose of the present study is to assess the clinical effects of real life usage of beta2-agonist (long-acting beta2-agonist, regular use of short-acting beta2 agonist, or oral beta2-agonist), as an add-on medication to inhaled steroids, in Arg/Arg and Gly/Gly patients with asthma.
  
  
  METHODS
  In a retrospective analysis of outpatient records, 27 patients with Arg/Arg and 35 patients with Gly/Gly had regular usage of beta2-agonist, whereas 37 patients with Arg/Arg and 29 patients with Gly/Gly had as-needed usage of beta2-agonist. During the follow-up periods at Hokkaido University Hospital, long term bronchodilator responses were assessed using 3 indexes: 1) improvement in FEV1 (DeltaFEV1 [ml]), 2) DeltaFEV1/FEV1 at an initial visit, 3) DeltaFEV1/predicted FEV1.
  
  
  RESULTS
  In patients with Gly/Gly genotype, compared with as-needed usage of beta2-agonist, the regular usage of beta2-agonist was associated with greater improvement in FEV1 in every index (p=0.027-0.041). In contrast, in patients with Arg/Arg genotype, the regular usage of beta2-agonist showed no greater improvement in FEV1 compared with as-needed beta2-agonist usage.
  
  
  CONCLUSIONS
  Gly/Gly and Arg/Arg genotype responses to regular usage of beta2-agonists may differ in patients with asthma.
authors.affiliation: Department of Respiratory Medicine, Hokkaido University School of Graduate Medicine. a-isa@med.hokudai.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Isada
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hizawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Shimizu
authors.forename: Kaoruko
authors.initials: K
authors.lastname: Shimizu
authors.forename: Ayumu
authors.initials: A
authors.lastname: Takahashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hattori
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Maeda
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Konno
authors.forename: Masaharu
authors.initials: M
authors.lastname: Nishimura
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D054770:G-Protein-Coupled Receptor Kinase 3 / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012189:Retrospective Studies
chemical_list: D000318:Adrenergic beta-Agonists; D054770:G-Protein-Coupled Receptor Kinase 3; C517848:GRK3 protein, human